Stocks Industrials EVGN
NASDAQ · IndustrialsEvogene Ltd. (EVGN)
Evogene Ltd. reported revenue of $3.9M in fiscal 2025, down 30.9% from a year earlier. It posted a net loss of $8.5M. In fiscal 2025 capital spending exceeded operating cash flow by $13.6M. At December 31, 2025 it held $13M in cash. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on March 26, 2026.
Key facts about Evogene Ltd.
- Net worth
- Evogene Ltd. has a market value (market cap) of $4.9M at the latest share price, and shareholders' equity of -$82K on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $3.9M (-30.9% year on year), with a net loss of $8.5M.
- Cash flow
- In fiscal 2025 operations used $13.5M of cash.
- Latest report
- The latest periodic report (annual report (foreign issuer), 20-F) was filed with the SEC on March 26, 2026 and covers the period to December 31, 2025. Open on SEC EDGAR
What Evogene Ltd. does
Evogene Ltd. is registered with the SEC under industry code SIC 2870 (Agricultural Chemicals). Its shares trade on NASDAQ under the ticker EVGN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $3.9M | -$8.5M | $1.08 | -$13.6M |
| 2024 | $5.6M | -$16.5M | -$2.90 | -$20.3M |
| 2023 | $3M | -$23.9M | -$5.20 | -$22.2M |
| 2022 | $1.7M | -$26.6M | -$6.44 | -$24.8M |
| 2021 | $930K | -$27.8M | -$6.84 | -$25.6M |
| 2020 | $1M | -$23.4M | -$8.22 | -$20.2M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where EVGN ranks in Industrials
Latest SEC filings
What Evogene Ltd. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 6, 2026Activist stake changed SCHEDULE 13D/A
- October 6, 2026
- September 30, 2026
- September 28, 2026
- September 28, 2026Form POS AM filing POS AM
- September 15, 2026
- September 11, 2026Activist stake changed SCHEDULE 13D/A
- September 11, 2026Activist stake changed SCHEDULE 13D/A
- September 4, 2026
- August 28, 2026Activist stake changed SCHEDULE 13D/A
Insider trades
What the people running Evogene Ltd. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 11, 2026 | Recanati LeonDirector | Bought | 460,000 | $292.1K |
| August 4, 2026 | Recanati LeonDirector | Bought | 800,000 | $400K |
| June 4, 2026 | Tarcic GabiChief Development Officer | Bought | 1,129 | $677.4 |
Who owns EVGN
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| L.I.A. Pure Capital Ltd.13D, may seek influence with 3 related filers | 16.94% | October 6, 2026 |
| Recanati Leon13D, may seek influence | 8.6% | September 11, 2026 |
Largest institutional holders
Insiders
2 insiders reported holding 1,345,015 shares in total, about $500.3K at the last price.
| Holder | Shares |
|---|---|
| Recanati LeonDirector | 1,343,886 |
| Tarcic GabiChief Development Officer | 1,129 |
Questions about EVGN
What does Evogene Ltd. do?
Evogene Ltd. is a company in the Industrials sector, listed on NASDAQ as EVGN. Its shares trade on NASDAQ under the ticker EVGN.
What is Evogene Ltd.'s net worth?
Evogene Ltd. has a market value (market cap) of $4.9M at the latest share price, and shareholders' equity of -$82K on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Evogene Ltd. profitable?
No. In fiscal 2025 it reported a net loss of $8.5M on revenue of $3.9M.
How much revenue does Evogene Ltd. make?
In fiscal 2025 Evogene Ltd. reported revenue of $3.9M. That is 30.9% less than a year earlier.
When did Evogene Ltd. last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on March 26, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the activist stake changed from October 6, 2026.
Similar companies
Compare EVGN with
Follow EVGN
Get an email when Evogene Ltd. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Evogene Ltd. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.